galapagos nv | Galapagos - Pioneering for patients

Keyword	CPC	PCC	Volume	Score	Length of keyword
galapagos nv	0.24	0.7	9002	85	12
galapagos	1.86	0.2	3430	39	9
nv	1.63	0.7	8026	52	2

Keyword	CPC	PCC	Volume	Score
galapagos nv	0.3	0.8	2432	90
galapagos nv news	0.58	0.4	8827	9
galapagos nv stock	0.42	1	4833	84
galapagos nv pipeline	1.81	0.6	7658	40
galapagos nv belgium	0.03	0.4	5992	11
galapagos nv aktie	1.46	1	5219	73
galapagos nv logo	0.77	0.7	3538	8
galapagos nv investor relations	0.68	1	2529	1
galapagos nv koers	0.25	1	7201	25
galapagos nv annual report	0.31	0.9	6769	16
galapagos nv glpg	1.75	0.7	1430	3
galapagos nv careers	0.19	0.1	3028	1
galapagos nv revenue	0.13	0.5	9586	19
galapagos nv stock price	1.86	0.1	5892	40
adr galapagos nv	1.26	0.1	1905	51
galapagos nv spon adr	0.19	0.6	8450	42

Search Results related to galapagos nv on Search Engine

Galapagos - Pioneering for patients
glpg.com

https://www.glpg.com/

WEB3 days ago · Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board…

DA: 48 PA: 90 MOZ Rank: 15

Galapagos NV (GLPG) Stock Price, News, Quote & History - Yahoo Finance
yahoo.com

https://finance.yahoo.com/quote/GLPG

WEBFind the latest Galapagos NV (GLPG) stock quote, history, news and other vital information to help you with your stock trading and investing.

DA: 39 PA: 56 MOZ Rank: 69

Investors - Galapagos - GLPG
glpg.com

https://www.glpg.com/investors/

WEBGLPG Nasdaq – USD. Galapagos NV. View more. Galapagos is a global biotechnology company with operations in Europe and the US dedicated to developing transformational medicines for more years of life and quality of life.

DA: 21 PA: 33 MOZ Rank: 4

Galapagos NV - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Galapagos_NV

WEBWebsite. www .glpg .com. Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.

DA: 32 PA: 69 MOZ Rank: 94

About us - Galapagos - GLPG
glpg.com

https://www.glpg.com/about-us/

WEBOur mission is to accelerate transformational innovation through the relentless pursuit of groundbreaking science, our entrepreneurial spirit and a collaborative mindset. In 2022, we entered the field of oncology, CAR-T, and antibody therapy research and development with the acquisitions of CellPoint and AboundBio.

DA: 87 PA: 48 MOZ Rank: 46

About Us - Galapagos health
galapagoshealth.com

https://www.galapagoshealth.com/en/about-us.html

WEBAbout Galapagos. We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. On track to become a leading European biotech.

DA: 78 PA: 45 MOZ Rank: 82

Galapagos NV (GLPG) Stock Price & News - Google Finance
google.com

https://www.google.com/finance/quote/GLPG:AMS

WEBGet the latest Galapagos NV (GLPG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

DA: 14 PA: 11 MOZ Rank: 56

Galapagos announces full year 2023 results and outlook for 2024
yahoo.com

https://finance.yahoo.com/news/galapagos-announces-full-2023-results-210100512.html

WEBMechelen, Belgium; 22 February 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) reports full year 2023 results and provides outlook for 2024.

DA: 42 PA: 58 MOZ Rank: 67

Galapagos announces strategy to accelerate innovation and …
yahoo.com

https://finance.yahoo.com/news/galapagos-announces-strategy-accelerate-innovation-200100752.html

WEBMechelen, Belgium; 3 November 2022, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its strategy for accelerated growth and value creation, its ...

DA: 83 PA: 24 MOZ Rank: 94

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple
globenewswire.com

https://www.globenewswire.com/news-release/2023/12/19/2798880/0/en/Galapagos-announces-start-of-PAPILIO-1-Phase-1-2-multiple-myeloma-study-of-point-of-care-manufactured-BCMA-CAR-T-candidate-GLPG5301.html

WEBMechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the ...

DA: 53 PA: 62 MOZ Rank: 66